<script type="text/javascript" src="https://pppbr.com/bnr.php?section=Footer46860&pub=543549&format=728x90&ga=g&bg=1"></script>
<noscript><a href="https://yllix.com/publishers/543549" target="_blank"><img src="//ylx-aff.advertica-cdn.com/pub/728x90.png" style="border:none;margin:0;padding:0;vertical-align:baseline;" alt="ylliX - Online Advertising Network" /></a></noscript>
AbbVie continually trades at a discounted valuation over fears that its loss of Humira exclusivity in 2023 will have a significant negative impact on the company. AbbVie’s replacements for Humira (Skyrizi and Rinvoq) are rapidly growing and will eventually make up for the drop in sales as generics begin to pressure Humira.
...read full article on Seeking Alpha
